{"text_format":"3","workbook":"xlsx","n_sheets":40,"sheets":["Document And Entity Information","Condensed Consolidated Balance ","Condensed Consolidated Balanc_2","Condensed Consolidated Statemen","Condensed Consolidated Statem_2","Condensed Consolidated Statem_3","Note 1 - Organization and Natur","Note 2 - Summary of Significant","Note 3 - Loss Per Share","Note 4 - Warrants","Note 5 - Stockholders' Equity, ","Note 6 - Commitments and Contin","Note 7 - Fair Value Measurement","Note 8 -Segment Information","Insider Trading Arrangements","Significant Accounting Policies","Note 2 - Summary of Significa_2","Note 3 - Loss Per Share (Tables","Note 4 - Warrants (Tables)","Note 5 - Stockholders' Equity_2","Note 7 - Fair Value Measureme_2","Note 2 - Summary of Significa_3","Note 2 - Summary of Significa_4","Note 3 - Loss Per Share (Detail","Note 3 - Loss Per Share - Sched","Note 3 - Loss Per Share - Antid","Note 3 - Loss Per Share - Ant_2","Note 4 - Warrants (Details Text","Note 4 - Warrants - Warrants Ou","Note 5 - Stockholders' Equity_3","Note 5 - Stockholders' Equity_4","Note 5 - Stockholders' Equity_5","Note 5 - Stockholders' Equity_6","Note 5 - Stockholders' Equity_7","Note 6 - Commitments and Cont_2","Note 7 - Fair Value Measureme_3","Note 7 - Fair Value Measureme_4","Note 7 - Fair Value Measureme_5","Note 7 - Fair Value Measureme_6","Note 8 -Segment Information (De"],"read":"whole","date_system":"1900"}

{"sheet":"Document And Entity Information","index":0,"n_rows":39,"n_cols":3,"rows_kept":39,"merged":[[0,0,1,0]]}
["Document And Entity Information - shares","3 Months Ended"]
[null,"Mar. 31, 2025","May 12, 2025"]
["Document Information [Line Items]"," "," "]
["Document Type","10-Q"," "]
["Document Quarterly Report","true"," "]
["Document Period End Date","Mar. 31,  2025"," "]
["Document Transition Report","false"," "]
["Entity File Number","001-38634"," "]
["Entity Registrant Name","Reviva Pharmaceuticals Holdings, Inc."," "]
["Entity Incorporation, State or Country Code","DE"," "]
["Entity Tax Identification Number","85-4306526"," "]
["Entity Address, Address Line One","10080 N. Wolfe Road, Suite SW3-200"," "]
["Entity Address, City or Town","Cupertino"," "]
["Entity Address, State or Province","CA"," "]
["Entity Address, Postal Zip Code","95014"," "]
["City Area Code","408"," "]
["Local Phone Number","501-8881"," "]
["Entity Current Reporting Status","Yes"," "]
["Entity Interactive Data Current","Yes"," "]
["Entity Filer Category","Non-accelerated Filer"," "]
["Entity Small Business","true"," "]
["Entity Emerging Growth Company","false"," "]
["Entity Shell Company","false"," "]
["Entity Common Stock, Shares Outstanding (in shares)"," ",{"v":46739949,"d":"46,739,949 "}]
["Entity Central Index Key","0001742927"," "]
["Current Fiscal Year End Date","--12-31"," "]
["Document Fiscal Year Focus","2025"," "]
["Document Fiscal Period Focus","Q1"," "]
["Amendment Flag","false"," "]
["Common Stock [Member]"," "," "]
["Document Information [Line Items]"," "," "]
["Title of 12(b) Security","Common Stock, par value $0.0001 per share"," "]
["Trading Symbol","RVPH"," "]
["Security Exchange Name","NASDAQ"," "]
["Warrant [Member]"," "," "]
["Document Information [Line Items]"," "," "]
["Title of 12(b) Security","Warrants to purchase one share of Common Stock"," "]
["Trading Symbol","RVPHW"," "]
["Security Exchange Name","NASDAQ"," "]

{"sheet":"Condensed Consolidated Balance ","index":1,"n_rows":25,"n_cols":3,"rows_kept":25}
["Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)","Mar. 31, 2025","Dec. 31, 2024"]
["Assets"," "," "]
["Cash and cash equivalents",{"v":5289404,"d":"$ 5,289,404"},{"v":13476331,"d":"$ 13,476,331"}]
["Prepaid clinical trial costs",{"v":211855,"d":"211,855 "},{"v":540601,"d":"540,601 "}]
["Prepaid expenses and other current assets",{"v":756066,"d":"756,066 "},{"v":666435,"d":"666,435 "}]
["Total current assets",{"v":6257325,"d":"6,257,325 "},{"v":14683367,"d":"14,683,367 "}]
["Non-current prepaid clinical trial costs",{"v":819721,"d":"819,721 "},{"v":819721,"d":"819,721 "}]
["Total Assets",{"v":7077046,"d":"7,077,046 "},{"v":15503088,"d":"15,503,088 "}]
["Liabilities"," "," "]
["Short-term debt",{"v":224300,"d":"224,300 "},{"v":458154,"d":"458,154 "}]
["Accounts payable",{"v":4721043,"d":"4,721,043 "},{"v":6283430,"d":"6,283,430 "}]
["Accrued clinical expenses",{"v":5524163,"d":"5,524,163 "},{"v":6723719,"d":"6,723,719 "}]
["Accrued compensation",{"v":556884,"d":"556,884 "},{"v":635587,"d":"635,587 "}]
["Other accrued liabilities",{"v":482864,"d":"482,864 "},{"v":500616,"d":"500,616 "}]
["Total current liabilities",{"v":11509254,"d":"11,509,254 "},{"v":14601506,"d":"14,601,506 "}]
["Warrant liabilities",{"v":27816,"d":"27,816 "},{"v":89010,"d":"89,010 "}]
["Total Liabilities",{"v":11537070,"d":"11,537,070 "},{"v":14690516,"d":"14,690,516 "}]
["Commitments and Contingencies"," "," "]
["Stockholders' Equity Note [Abstract]"," "," "]
["Common stock, par value of $0.0001; 315,000,000 shares authorized; 46,739,949 and 46,579,199 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively",{"v":4674,"d":"4,674 "},{"v":4658,"d":"4,658 "}]
["Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Additional paid-in capital",{"v":166241192,"d":"166,241,192 "},{"v":165080964,"d":"165,080,964 "}]
["Accumulated deficit",{"v":-170705890,"d":"(170,705,890)"},{"v":-164273050,"d":"(164,273,050)"}]
["Total stockholders' equity (deficit)",{"v":-4460024,"d":"(4,460,024)"},{"v":812572,"d":"812,572 "}]
["Total Liabilities and Stockholders' Equity (Deficit)",{"v":7077046,"d":"$ 7,077,046"},{"v":15503088,"d":"$ 15,503,088"}]

{"sheet":"Condensed Consolidated Balanc_2","index":2,"n_rows":9,"n_cols":3,"rows_kept":9}
["Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares","Mar. 31, 2025","Dec. 31, 2024"]
["Common stock, par value (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Common stock, shares authorized (in shares)",{"v":315000000,"d":"315,000,000 "},{"v":315000000,"d":"315,000,000 "}]
["Common Stock, Shares, Outstanding (in shares)",{"v":46739949,"d":"46,739,949 "},{"v":46579199,"d":"46,579,199 "}]
["Common Stock, Shares, Issued (in shares)",{"v":46739949,"d":"46,739,949 "},{"v":46579199,"d":"46,579,199 "}]
["Preferred Stock, Par or Stated Value Per Share (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]
["Preferred Stock, Shares Authorized (in shares)",{"v":10000000,"d":"10,000,000 "},{"v":10000000,"d":"10,000,000 "}]
["Preferred Stock, Shares Issued (in shares)",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Preferred Stock, Shares Outstanding (in shares)",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]

{"sheet":"Condensed Consolidated Statemen","index":3,"n_rows":20,"n_cols":3,"rows_kept":20,"merged":[[0,0,1,0],[0,1,0,2]]}
["Condensed Consolidated Statements of Operations (Unaudited) - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Operating expenses"," "," "]
["Research and development",{"v":4113537,"d":"$ 4,113,537"},{"v":5783865,"d":"$ 5,783,865"}]
["General and administrative",{"v":2424630,"d":"2,424,630 "},{"v":2138241,"d":"2,138,241 "}]
["Total operating expenses",{"v":6538167,"d":"6,538,167 "},{"v":7922106,"d":"7,922,106 "}]
["Loss from operations",{"v":-6538167,"d":"(6,538,167)"},{"v":-7922106,"d":"(7,922,106)"}]
["Other income (expense)"," "," "]
["Gain on remeasurement of warrant liabilities",{"v":61194,"d":"61,194 "},{"v":456177,"d":"456,177 "}]
["Interest expense",{"v":-11620,"d":"(11,620)"},{"v":-3487,"d":"(3,487)"}]
["Interest income",{"v":86111,"d":"86,111 "},{"v":173098,"d":"173,098 "}]
["Other (expense) income, net",{"v":-25145,"d":"(25,145)"},{"v":-129894,"d":"(129,894)"}]
["Total other (expense) income, net",{"v":110540,"d":"110,540 "},{"v":495894,"d":"495,894 "}]
["Loss before provision for income taxes",{"v":-6427627,"d":"(6,427,627)"},{"v":-7426212,"d":"(7,426,212)"}]
["Provision for income taxes",{"v":5213,"d":"5,213 "},{"v":7396,"d":"7,396 "}]
["Net loss",{"v":-6432840,"d":"$ (6,432,840)"},{"v":-7433608,"d":"$ (7,433,608)"}]
["Net loss per share:"," "," "]
["Basic and diluted (in dollars per share)",{"v":-0.13,"d":"$ (0.13)"},{"v":-0.25,"d":"$ (0.25)"}]
["Weighted average shares outstanding"," "," "]
["Basic and diluted (in shares)",{"v":48644339,"d":"48,644,339 "},{"v":29887325,"d":"29,887,325 "}]

{"sheet":"Condensed Consolidated Statem_2","index":4,"n_rows":15,"n_cols":5,"rows_kept":15}
["Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)","Common Stock [Member]","Additional Paid-in Capital [Member]","Retained Earnings [Member]","Total"]
["Balance (in shares) at Dec. 31, 2023",{"v":27918560,"d":"27,918,560 "}," "," "," "]
["Balance at Dec. 31, 2023",{"v":2792,"d":"$ 2,792"},{"v":140070172,"d":"$ 140,070,172"},{"v":-134354248,"d":"$ (134,354,248)"},{"v":5718716,"d":"$ 5,718,716"}]
["Stock-based compensation expense",{"v":0,"d":"0 "},{"v":369075,"d":"369,075 "},{"v":0,"d":"0 "},{"v":369075,"d":"369,075 "}]
["Net loss",{"v":0,"d":"$ 0"},{"v":0,"d":"0 "},{"v":-7433608,"d":"(7,433,608)"},{"v":-7433608,"d":"(7,433,608)"}]
["Balance (in shares) at Mar. 31, 2024",{"v":27918560,"d":"27,918,560 "}," "," "," "]
["Balance at Mar. 31, 2024",{"v":2792,"d":"$ 2,792"},{"v":140439247,"d":"140,439,247 "},{"v":-141787856,"d":"(141,787,856)"},{"v":-1345817,"d":"(1,345,817)"}]
["Balance (in shares) at Dec. 31, 2024",{"v":46579199,"d":"46,579,199 "}," "," "," "]
["Balance at Dec. 31, 2024",{"v":4658,"d":"$ 4,658"},{"v":165080964,"d":"165,080,964 "},{"v":-164273050,"d":"(164,273,050)"},{"v":812572,"d":"812,572 "}]
["Class of Warrant or Right, Exercised During Period (in shares)",{"v":160750,"d":"160,750 "}," "," "," "]
["Common stock issued in connection with prefunded warrant exercises",{"v":16,"d":"$ 16"},{"v":241109,"d":"241,109 "},{"v":0,"d":"0 "},{"v":241125,"d":"241,125 "}]
["Stock-based compensation expense",{"v":0,"d":"0 "},{"v":919119,"d":"919,119 "},{"v":0,"d":"0 "},{"v":919119,"d":"919,119 "}]
["Net loss",{"v":0,"d":"$ 0"},{"v":0,"d":"0 "},{"v":-6432840,"d":"(6,432,840)"},{"v":-6432840,"d":"(6,432,840)"}]
["Balance (in shares) at Mar. 31, 2025",{"v":46739949,"d":"46,739,949 "}," "," "," "]
["Balance at Mar. 31, 2025",{"v":4674,"d":"$ 4,674"},{"v":166241192,"d":"$ 166,241,192"},{"v":-170705890,"d":"$ (170,705,890)"},{"v":-4460024,"d":"$ (4,460,024)"}]

{"sheet":"Condensed Consolidated Statem_3","index":5,"n_rows":24,"n_cols":3,"rows_kept":24,"merged":[[0,0,1,0],[0,1,0,2]]}
["Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Cash flows from operating activities"," "," "]
["Net loss",{"v":-6432840,"d":"$ (6,432,840)"},{"v":-7433608,"d":"$ (7,433,608)"}]
["Adjustments to reconcile net loss to net cash used in operating activities"," "," "]
["Change in fair value of warrant liabilities",{"v":-61194,"d":"(61,194)"},{"v":-456177,"d":"(456,177)"}]
["Stock-based compensation expense",{"v":919119,"d":"919,119 "},{"v":369075,"d":"369,075 "}]
["Changes in operating assets and liabilities:"," "," "]
["Prepaid clinical trial costs (current and non-current)",{"v":328746,"d":"328,746 "},{"v":-701307,"d":"(701,307)"}]
["Prepaid expenses and other current assets",{"v":-89631,"d":"(89,631)"},{"v":-488744,"d":"(488,744)"}]
["Accounts payable",{"v":-1562387,"d":"(1,562,387)"},{"v":1871347,"d":"1,871,347 "}]
["Accrued expenses and other current liabilities",{"v":-1296011,"d":"(1,296,011)"},{"v":-4886395,"d":"(4,886,395)"}]
["Net cash used in operating activities",{"v":-8194198,"d":"(8,194,198)"},{"v":-11725809,"d":"(11,725,809)"}]
["Cash flows from financing activities"," "," "]
["Proceeds from issuance of short-term debt",{"v":0,"d":"0 "},{"v":415000,"d":"415,000 "}]
["Repayment of short-term debt",{"v":-233854,"d":"(233,854)"},{"v":-83000,"d":"(83,000)"}]
["Proceeds from exercise of warrants",{"v":241125,"d":"241,125 "},{"v":0,"d":"0 "}]
["Net cash provided by financing activities",{"v":7271,"d":"7,271 "},{"v":332000,"d":"332,000 "}]
["Net decrease in cash and cash equivalents",{"v":-8186927,"d":"(8,186,927)"},{"v":-11393809,"d":"(11,393,809)"}]
["Cash and cash equivalents, beginning of period",{"v":13476331,"d":"13,476,331 "},{"v":23367456,"d":"23,367,456 "}]
["Cash and cash equivalents, end of period",{"v":5289404,"d":"5,289,404 "},{"v":11973647,"d":"11,973,647 "}]
["Supplemental disclosures of cash flow information:"," "," "]
["Cash paid for taxes",{"v":1075,"d":"1,075 "},{"v":657,"d":"657 "}]
["Cash paid for interest",{"v":10158,"d":"$ 10,158"},{"v":3487,"d":"$ 3,487"}]

{"sheet":"Note 1 - Organization and Natur","index":6,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 1 - Organization and Nature of Operations","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]","1. ORGANIZATION AND NATURE OF OPERATIONS On December 14, 2020, Reviva Pharmaceuticals Holdings, Inc. (the “Company”), a Delaware corporation and the successor by re-domiciliation to Tenzing Acquisition Corp. (“Tenzing”), a British Virgin Islands exempted company, Tenzing Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Tenzing (“Merger Sub”), and Reviva Pharmaceuticals, Inc., a Delaware corporation (together with its consolidated subsidiary), consummated a business combination (the “Business Combination”) through the merger of Merger Sub with and into Reviva Pharmaceuticals, Inc. (the \"Merger\"), in accordance with the Agreement and Plan of Merger, dated as of July 20, 2020 (the “Merger Agreement”), by and among Tenzing, Merger Sub, Reviva Pharmaceuticals, Inc., and the other parties thereto. Pursuant to the Merger Agreement, at the effective time of the Merger, Merger Sub merged with and into Reviva Pharmaceuticals, Inc., with Reviva Pharmaceuticals, Inc. as the surviving company in the Merger and, after giving effect to such Merger, Reviva Pharmaceuticals, Inc. becoming a wholly-owned subsidiary of Reviva Pharmaceuticals Holdings, Inc. In these notes to the unaudited condensed consolidated financial statements, unless otherwise specified or the context indicates otherwise, references to the “Company,” “Reviva,” “we,” “us” and “our” refer to Reviva Pharmaceuticals Holdings, Inc. and its consolidated subsidiaries. Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 and its Indian subsidiary, Reviva Pharmaceuticals India Pvt. Ltd. was incorporated in 2014. The Company is a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system (\"CNS\"), inflammatory and cardiometabolic diseases."]

{"sheet":"Note 2 - Summary of Significant","index":7,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 2 - Summary of Significant Accounting Policies and Basis of Presentation","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Significant Accounting Policies [Text Block]","2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain footnotes and other financial information normally required by accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted in accordance with such rules and regulations. In management’s opinion, these unaudited condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and notes thereto and include all adjustments, consisting of normal recurring items, considered necessary for the fair presentation. The operating results for the three months ended March 31, 2025 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2025. The unaudited condensed consolidated balance sheet as of December 31, 2024, has been derived from our audited financial statements at that date but does not include all disclosures and financial information required by U.S. GAAP for complete financial statements. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2024, which were included in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (“SEC”) on April 3, 2025. Principles of consolidation The accompanying condensed consolidated financial statements include the accounts of Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiaries Reviva Pharmaceuticals, Inc. and Reviva Pharmaceuticals India Pvt. Ltd. The Company's foreign subsidiary’s functional currency is the U.S. dollar. The Company recognizes a foreign currency gain or loss each reporting period, on translation of its foreign subsidiary's financial information on consolidation. Any such foreign currency gain or loss is recognized as part of other (expense) income, net, on the condensed consolidated statement of operations. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. All transactions and balances between the parent and its subsidiaries have been eliminated in consolidation. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker (“CODM”), the Company’s chief executive officer, view the Company’s operations and manage its business as a single operating segment. See Note 8, \"Segment Information,\" for more information. Liquidity and going concern The Company has incurred losses since inception and as of March 31, 2025 the Company had a working capital deficit of approximately $5.3 million, an accumulated deficit of $170.7 million and cash and cash equivalents on hand of approximately $5.3 million. The Company's net loss for the three months ended March 31, 2025 and 2024, was approximately $6.4 million and $7.4 million, respectively. The Company expects to incur significant expenses and increased operating losses for the next several years. The Company expects its expenses to increase in connection with its ongoing activities to research, develop and commercialize its product candidates. The Company will need to generate significant revenues to achieve profitability, and it may never do so. The Company’s current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. The Company believes that it has adequate cash on hand to cover anticipated outlays through the end of the second quarter of 2025, but will need additional fundraising activities and cash on hand during the third quarter of fiscal year 2025. The Company has based this estimate, however, on assumptions that may prove to be wrong, and could spend available financial resources much faster than it currently expects. The Company will need to raise additional funds to continue funding its development efforts and operations. The Company intends to secure such additional funding, although there are no guarantees or commitments for additional funding. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. The Company will seek to fund its operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain clinical activities. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods covered by the consolidated financial statements and accompanying notes. Significant items subject to such estimates and assumptions include clinical trial costs, fair value of stock-based compensation, and fair value of warrants. Actual results could differ materially from such estimates under different assumptions or circumstances. Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all the Company’s cash and cash equivalents are held in demand deposit and money market funds at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. Amounts held in demand deposit in excess of federally insured limits, totaled $1,093,816 and $937,004 as of March 31, 2025 and December 31, 2024, respectively. The Company has not experienced any losses on its deposits of cash. The Company is subject to all of the risks inherent in a clinical-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company contracts with vendors and consultants to provide services related to the Company’s research and development. Costs and expenses incurred that represented 10% or more of research and development costs for the three months ended March 31, 2025 and 2024 consisted of the following: during the three months ended March 31, 2025, costs from three two The Company’s operating results may be materially affected by the foregoing factors. Cash and cash equivalents As of March 31, 2025, and December 31, 2024, the Company’s cash was maintained in demand deposit forms at three financial institutions. The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents. The components of cash and cash equivalents were as follows:\nAs of March 31, 2025\nAs of December 31, 2024\nCash on deposit $ 1,427,974 $ 1,272,704\nMoney market funds (cash equivalents) 3,861,430 12,203,627\nCash and cash equivalents $ 5,289,404 $ 13,476,331 Fair value measurements Accounting Standards Codification (\"ASC\") 820, Fair Value Measurements , The three levels of the fair value hierarchy under ASC 820 are described below:\n•\nLevel 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.\n•\nLevel 2 - Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.\n•\nLevel 3 - Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. In determining the fair value of equity classified warrants, the Company utilizes the Black-Scholes-Merton model using assumptions regarding volatility of the Company's common share price, expected term of the warrants, expected divided rate, and risk-free interest rates. In determining the fair value of liability classified warrants, the Company utilizes a Lattice model using assumptions regarding volatility of the Company's common share price, expected term of the warrants, expected dividend, and risk-free interest rates. These assumptions are described as:\n•\nExpected term:\n•\nExpected volatility:\n•\nExpected dividend:\n•\nRisk-free interest rate: Due to their short maturities, the carrying amounts for cash and cash equivalents, prepaid clinical trial costs, prepaid expenses and other current assets, accounts payable, accrued clinical expenses, accrued compensation, short-term debt, and other accrued liabilities approximate their fair value. Clinical trial costs We record clinical trial costs as they are incurred. For any unbilled costs as of each reporting date, we determine the amounts to accrue by obtaining reports from the Company’s contract research organization (“CRO”) and communicating with our personnel and suppliers to identify services that have been performed, but not yet billed. We further validate the completeness of our accruals by reconciling payments and invoices, and reviewing vendor contracts and purchase orders. As necessary, we obtain milestones and percentage completion reports from vendors and will estimate the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual cost. Our estimated accrued expenses are based on facts and circumstances known to us at that time. We will confirm the accuracy of our estimates with the service providers and adjust if necessary. The significant estimates in our accrued clinical trial costs include the calculation of patient visits incurred, but not yet reported by the vendor. The calculation involves the use of key inputs and assumptions such as estimated budget, estimated unreported costs based on historical trending of reported costs to date, and projected costs remaining until the conclusion of the trials. These estimates are primarily based on communications with the third-party service providers, the Company’s estimates of accrued clinical trial costs and information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the consolidated financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary. Short-term debt In December 2024, the Company obtained new financing for certain policy premiums related to Director and Officers liability insurance. The governing agreement assigns the lender a first priority lien on and security interest in the financed policies and any additional premium required in the financed policies. The total premiums, taxes, and fees financed was $458,154. The financing arrangement has an annual percentage interest rate of 7.90% and a term of 10 months, with ten payments, inclusive of interest, payable on a monthly basis beginning January 2025 and continuing through October 2025. New accounting pronouncements not yet adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes Improvements to Income Tax Disclosures In November 2024, the FASB issued ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses"]

{"sheet":"Note 3 - Loss Per Share","index":8,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 3 - Loss Per Share","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Earnings Per Share [Text Block]","3. NET LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common shares and pre-funded warrants outstanding during the period. Diluted net loss per share includes potentially dilutive securities such as stock options, and warrants to purchase common stock (excluding warrants that are exercisable for $0.0001 per warrant) unless the result of inclusion would be anti-dilutive. These securities have been excluded from the calculation of diluted net loss per share for the three months ended March 31, 2025 and 2024, because all such securities are anti-dilutive for all periods presented. The components of basic and diluted net loss per share were as follows:\nThree Months Ended March 31,\n2025\n2024\nNumerator:\nNet loss $ (6,432,840 ) $ (7,433,608 )\nDenominator:\nWeighted-average common shares outstanding – basic and diluted 48,644,339 29,887,325\nNet loss per share – basic and diluted $ (0.13 ) $ (0.25 ) The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive:\nThree Months Ended March 31,\n2025\n2024\nShares issuable upon exercise of stock options 3,454,190 1,560,574\nShares issuable upon exercise of warrants to purchase common stock (excluding 1,968,765 warrants that are exercisable for $0.0001 per warrant as of March 31, 2025 and 2024) 45,621,853 20,883,869\n49,076,043 22,444,443 The diluted net loss per share computation equals basic net loss per share for the three months ended March 31, 2025 and 2024, because the Company had a net loss and the impact of the assumed exercise of stock options and certain warrants would be anti-dilutive. "]

{"sheet":"Note 4 - Warrants","index":9,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 4 - Warrants","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Warrants [Text Block]","4. WARRANTS The following is a summary of the Company’s warrant activity (number of common stock shares underlying the warrants) for the three months ended March 31, 2025:\nWarrant Issuance\nIssuance\nExercise Price\nOutstanding, December 31, 2024\nWarrant Shares Granted\nWarrant Shares Exercised\nWarrant Shares Cancelled/ Expired\nOutstanding, March 31 2025\nExpiration\nSPAC Public Warrants\nDecember 2020 $ 11.50 6,881,313 — — — 6,881,313\nDecember 2025\nJune 2021 Common Stock Warrants\nJune 2021 $ 4.125 4,445,066 — — — 4,445,066\nMay 2026\nJune 2021 Common Stock Warrants (August 2024 Amended)*\nJune 2021 $ 0.7964 2,199,975 — — — 2,199,975\nAugust 2029\nPre-Public Private Company Warrants\nDecember 2020 $ 22.99 120,456 — — — 120,456\nJuly 2025\nSeptember 2022 Private Pre-Funded Warrants\nSeptember 2022 $ 0.0001 1,383,399 — — — 1,383,399\nSeptember 2027\nSeptember 2022 Common Stock Warrants\nSeptember 2022 $ 2.40 1,383,399 — — — 1,383,399\nSeptember 2027\nNovember 2023 Common Stock Warrants\nNovember 2023 $ 5.00 1,951,220 — — — 1,951,220\nNovember, 2028\nNovember 2023 Common Stock Warrants (May 2024 Amended)**\nNovember 2023 $ 1.455 1,365,854 — — — 1,365,854\nMay 2029\nNovember 2023 Common Stock Warrants (August 2024 Amended)***\nNovember 2023 $ 0.7964 2,536,586 — — — 2,536,586\nAugust 2029\nNovember 2023 Pre-Funded Warrants\nNovember 2023 $ 0.0001 585,366 — — — 585,366\nNovember, 2028\nMay 2024 Common Stock Warrants\nMay 2024 $ 1.455 1,898,734 — — — 1,898,734\nMay 2029\nAugust 2024 Common Stock Warrants\nAugust 2024 $ 0.7964 4,761,905 — — — 4,761,905\nAugust 2029\nAugust 2024 Underwriter Warrants\nAugust 2024 $ 1.3125 238,095 — — — 238,095\nAugust 2029\nDecember 2024 Series A Common Stock Warrants\nDecember 2024 $ 1.50 6,000,000 — (55,250 ) — 5,944,750\nJune 2025\nDecember 2024 Series B Common Stock Warrants\nDecember 2024 $ 1.50 12,000,000 — (105,500 ) — 11,894,500\nDecember 2029\n47,751,368 — (160,750 ) — 47,590,618 * In August 2024, 2,199,975 of these warrants were modified to reduce the exercise price from $4.125 per warrant share, to $0.7964 per warrant share and to extend the expiration of these warrants from May 2026 to August 2029. ** In May 2024, 1,365,854 of these warrants were modified to reduce the exercise price from $5.00 per warrant share, to $1.455 per warrant share and to extend the expiration of these warrants from November 2028 to May 2029. *** In August 2024, 2,536,586 of these warrants (separate from the May 2024 modification) were modified to reduce the exercise price from $5.00 per warrant share, to $0.7964 per warrant share and to extend the expiration of these warrants from November 2028 to August 2029. "]

{"sheet":"Note 5 - Stockholders' Equity, ","index":10,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Share-Based Payment Arrangement [Text Block]","5. STOCKHOLDERS' EQUITY, STOCK OPTION PLANS, AND STOCK-BASED COMPENSATION Our authorized capital stock consists of:\n•\n315,000,000 shares of common stock, par value $0.0001 per share; and\n•\n10,000,000 shares of preferred stock, par value $0.0001 per share. As of March 31, 2025 there were 46,739,949 shares of our common stock outstanding, and no no As of March 31, 2025, the Company has shares of common stock reserved for future issuance as follows:\nShares underlying outstanding warrants 47,590,618\nShares reserved for future grants under the 2020 Equity Incentive Plan 6,823,675\nShares underlying outstanding stock options 3,454,190\nTotal common stock reserved for future issuance 57,868,483 2020 Equity Incentive Plan Subsequent to the December 31, 2024 balance sheet date, in accordance with the “evergreen” provision in our 2020 Equity Incentive Plan (the \"Evergreen Provision\"), an additional 4,657,919 shares were automatically made available for issuance on the first day of 2025, which represents 10% of the number of shares of common stock outstanding on December 31, 2024. Stock-based Compensation Expense The Company records stock-based compensation expense based on the fair value of stock options granted to employees, non-employee consultants and non-employee directors. During the three months ended March 31, 2025 and 2024, the Company recorded stock-based compensation expense of approximately $0.9 million and $0.4 million, respectively. As of March 31, 2025, the Company had unrecognized stock-based compensation expense of $2.7 million, which is expected to be recognized over a weighted-average period of 1.9 years. Determining Fair Value Valuation and Recognition – The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes pricing model utilizes assumptions regarding volatility of the Company's common share price, expected term, expected divided rate, and risk-free interest rates as described below:\n•\nExpected term:\n•\nExpected volatility:\n•\nExpected dividend:\n•\nRisk-free interest rate: The fair value of options granted during the three months ended March 31, 2025 used the following assumptions and key inputs:\nBlack-Scholes-Merton Inputs\nMarch 31, 2025\nRisk-free interest rate 4.40 %\nExpected term (in years) 5.38\nExpected volatility 110.00 %\nExpected dividend yield — % The weighted average fair value of stock options granted for the three months ended March 31, 2025 was $1.48. The options have a contractual term of 10 years. No Activity under the Company's equity compensation plan for the three months ended March 31, 2025 is as follows:\nShares Available for Grant\nNumber of Options Outstanding\nWeighted Average Exercise price per share\nWeighted Average Remaining Contractual Term in Years\nAggregate Intrinsic Value\nBalance, December 31, 2024 3,060,506 2,559,440 $ 4.07 8.88 $ 683,016\nGranted (894,750 ) 894,750 1.80\nEvergreen plan increase 4,657,919\nBalance, March 31, 2025 6,823,675 3,454,190 $ 3.48 8.95 $ 1,219\nOptions vested and exercisable at March 31, 2025 2,143,223 $ 3.98 8.72 $ 1,219 For the three months ended March 31, 2025 and 2024, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows:\nThree Months Ended, March 31\n2025\n2024\nResearch and development $ 313,862 $ 194,896\nGeneral and administrative 605,257 174,179\nTotal stock-based compensation expense $ 919,119 $ 369,075 "]

{"sheet":"Note 6 - Commitments and Contin","index":11,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 6 - Commitments and Contingencies","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Commitments and Contingencies Disclosure [Text Block]","6. COMMITMENTS AND CONTINGENCIES Clinical trials Since 2010, the Company has entered into multiple clinical trial agreements with medical institutions in the United States, Europe and Asia for the purpose of enrolling patients into various clinical trials. The agreements are substantially similar by trial and include a detailed listing of the clinical trial services for which the Company will pay, how much will be paid for each service, a set-up charge (if any), Investigational Review Board fees, contractual term, and other provisions. The clinical trial services provided by each site generally include the screening of prospective patients and, for those patients to be enrolled in the study, administration of the Company’s investigation drug according to the trial protocol, any required hospitalization, ancillary medical supplies, and patient follow-up. Further, each agreement requires the Company to indemnify each respective clinical site against any and all liability, loss, or damage it may suffer as a result of third-party claims; the Company maintains product liability insurance in conjunction with this indemnification. The agreements may be terminated upon 30 days’ written notice, subject to conditions of paying all liabilities incurred through the date of termination. Additionally, with each screened patient, the Company incurs expense with other entities engaged to provide independent review of patient medical records. Indemnification From time to time, in its normal course of business, the Company may indemnify other parties, with whom it enters into contractual relationships, including lessors and parties to other transactions with the Company. The Company may agree to hold other parties harmless against specific losses, such as those that could arise from a breach of representation, covenant or third-party infringement claims. It may not be possible to determine the maximum potential amount of liability under such indemnification obligations due to the unique facts and circumstances that are likely to be involved in each particular claim and indemnification provision. Historically, there have been no such indemnification claims. The Company has also indemnified its directors and executive officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer. Operating Leases The Company leases a corporate office located at 10080 N. Wolfe Road, Suite SW3-200, Cupertino, CA 95014. The lease was entered into beginning December 1, 2023 for a 12-month term with a monthly lease payment of approximately $4,300. The lease was renewed in January 2025 for an additional twelve months Litigation The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. "]

{"sheet":"Note 7 - Fair Value Measurement","index":12,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 7 - Fair Value Measurements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Fair Value Disclosures [Text Block]","7. FAIR VALUE MEASUREMENTS The following tables provide a summary of the assets and liabilities that are required to be measured at fair value on a recurring basis and where they are classified within the fair value hierarchy as of March 31, 2025 and December 31, 2024:\nMarch 31, 2025\nLevel 1\nLevel 2\nLevel 3\nTotal\nAssets:\nMoney market funds (cash equivalents) $ 3,861,430 $ — $ — $ 3,861,430\nTotal assets measured and recorded at fair value $ 3,861,430 $ — $ — $ 3,861,430\nLiabilities:\nWarrant liabilities $ — $ — $ 27,816 $ 27,816\nTotal liabilities measured and recorded at fair value $ — $ — $ 27,816 $ 27,816\nDecember 31, 2024\nLevel 1\nLevel 2\nLevel 3\nTotal\nAssets:\nMoney market funds (cash equivalents) $ 12,203,627 $ — $ — $ 12,203,627\nTotal assets measured and recorded at fair value $ 12,203,627 $ — $ — $ 12,203,627\nLiabilities:\nWarrant liabilities $ — $ — $ 89,010 $ 89,010\nTotal liabilities measured and recorded at fair value $ — $ — $ 89,010 $ 89,010 The following table summarizes the changes in the fair value of the warrant liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):\nThree Months Ended March 30,\n2025\n2024\nBalance, beginning of period $ 89,010 $ 806,655\nChange in fair value of warrant liabilities (61,194 ) (456,177 )\nBalance, end of period $ 27,816 $ 350,478 In prior years, the Company issued warrants to purchase 556,313 shares of common stock in a private-placement (the \"Private Warrants\") and classified the warrants as derivative liabilities, pursuant to ASC 815, as the Private Warrants have an exercise price that is subject to potential adjustment, with subsequent changes in their fair values to be recognized in the condensed consolidated statement of operations at each reporting date. The Company calculated the fair value of the Private Warrants as of March 31, 2025 and December 31, 2024 as $27,816 and $89,010, respectively, using a Lattice model. The assumptions and key inputs used in the Lattice calculation were the following:\nMarch 31, 2025\nDecember 31, 2024\nRisk-free interest rate 4.15 % 4.17 %\nRemaining expected term of Private Warrants 0.71 0.95\nExpected volatility (1) 163.50 % 128.70 %\nStock price on valuation date $ 0.95 $ 1.81\nExercise price $ 11.50 $ 11.50\nExpected dividend — % — % (1) "]

{"sheet":"Note 8 -Segment Information","index":13,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 8 -Segment Information","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes to Financial Statements"," "]
["Segment Reporting Disclosure [Text Block]","8. SEGMENT INFORMATION The Company views its operations and manages its business as one Consistent with the Company's management reporting, results of operations are reported on a consolidated basis for purposes of segment reporting. Net loss is used to allocate resources and is reported on the condensed consolidated statements of operations. The measure of segment assets is reported on the condensed consolidated balance sheets as cash and cash equivalents. The CODM does not review any measure of significant segment expenses or segment loss which differ from the level of reporting as reflected on the condensed consolidated statement of operations. "]

{"sheet":"Insider Trading Arrangements","index":14,"n_rows":8,"n_cols":2,"rows_kept":8,"merged":[[0,0,1,0]]}
["Insider Trading Arrangements","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Trading Arrangements, by Individual [Table]"," "]
["Material Terms of Trading Arrangement [Text Block]","OTHER INFORMATION. Notice of Failure to Satisfy a Continued Listing Rule or Standard Nasdaq Minimum Bid Price Rule On May 13, 2025, we received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive business days, and that we are therefore not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing or trading of our common stock on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), we have a period of 180 calendar days, or until November 10, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period. If we are not in compliance by November 10, 2025, we may qualify for a second 180 calendar-day period to regain compliance. If we do not qualify for, or fail to regain compliance during the second compliance period, then Nasdaq will notify us of Nasdaq’s determination to delist our common stock, at which point we would have an option to appeal the delisting determination to a Nasdaq hearings panel. We intend to actively monitor the closing bid price of our common stock and may, if appropriate, consider implementing available strategies to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Rule 10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements During the fiscal quarter ended March 31, 2025, none "]
["Rule 10b5-1 Arrangement Adopted [Flag]","false"]
["Non-Rule 10b5-1 Arrangement Adopted [Flag]","false"]
["Rule 10b5-1 Arrangement Terminated [Flag]","false"]
["Non-Rule 10b5-1 Arrangement Terminated [Flag]","false"]

{"sheet":"Significant Accounting Policies","index":15,"n_rows":14,"n_cols":2,"rows_kept":14,"merged":[[0,0,1,0]]}
["Significant Accounting Policies (Policies)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Accounting Policies [Abstract]"," "]
["Basis of Accounting, Policy [Policy Text Block]","Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Certain footnotes and other financial information normally required by accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted in accordance with such rules and regulations. In management’s opinion, these unaudited condensed consolidated financial statements have been prepared on the same basis as our annual consolidated financial statements and notes thereto and include all adjustments, consisting of normal recurring items, considered necessary for the fair presentation. The operating results for the three months ended March 31, 2025 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2025. The unaudited condensed consolidated balance sheet as of December 31, 2024, has been derived from our audited financial statements at that date but does not include all disclosures and financial information required by U.S. GAAP for complete financial statements. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and notes thereto for the year ended December 31, 2024, which were included in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (“SEC”) on April 3, 2025."]
["Consolidation, Policy [Policy Text Block]","Principles of consolidation The accompanying condensed consolidated financial statements include the accounts of Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiaries Reviva Pharmaceuticals, Inc. and Reviva Pharmaceuticals India Pvt. Ltd. The Company's foreign subsidiary’s functional currency is the U.S. dollar. The Company recognizes a foreign currency gain or loss each reporting period, on translation of its foreign subsidiary's financial information on consolidation. Any such foreign currency gain or loss is recognized as part of other (expense) income, net, on the condensed consolidated statement of operations. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. All transactions and balances between the parent and its subsidiaries have been eliminated in consolidation. "]
["Segment Reporting, Policy [Policy Text Block]","Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation and used by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company and the Company’s chief operating decision-maker (“CODM”), the Company’s chief executive officer, view the Company’s operations and manage its business as a single operating segment. See Note 8, \"Segment Information,\" for more information. "]
["Going Concern [Policy Text Block]","Liquidity and going concern The Company has incurred losses since inception and as of March 31, 2025 the Company had a working capital deficit of approximately $5.3 million, an accumulated deficit of $170.7 million and cash and cash equivalents on hand of approximately $5.3 million. The Company's net loss for the three months ended March 31, 2025 and 2024, was approximately $6.4 million and $7.4 million, respectively. The Company expects to incur significant expenses and increased operating losses for the next several years. The Company expects its expenses to increase in connection with its ongoing activities to research, develop and commercialize its product candidates. The Company will need to generate significant revenues to achieve profitability, and it may never do so. The Company’s current cash on hand is not sufficient to satisfy its operating cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. The Company believes that it has adequate cash on hand to cover anticipated outlays through the end of the second quarter of 2025, but will need additional fundraising activities and cash on hand during the third quarter of fiscal year 2025. The Company has based this estimate, however, on assumptions that may prove to be wrong, and could spend available financial resources much faster than it currently expects. The Company will need to raise additional funds to continue funding its development efforts and operations. The Company intends to secure such additional funding, although there are no guarantees or commitments for additional funding. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the financial statements are issued. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. The Company will seek to fund its operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing certain clinical activities. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. "]
["Use of Estimates, Policy [Policy Text Block]","Use of estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods covered by the consolidated financial statements and accompanying notes. Significant items subject to such estimates and assumptions include clinical trial costs, fair value of stock-based compensation, and fair value of warrants. Actual results could differ materially from such estimates under different assumptions or circumstances. "]
["Concentration Risk, Credit Risk, Policy [Policy Text Block]","Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all the Company’s cash and cash equivalents are held in demand deposit and money market funds at three financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. Amounts held in demand deposit in excess of federally insured limits, totaled $1,093,816 and $937,004 as of March 31, 2025 and December 31, 2024, respectively. The Company has not experienced any losses on its deposits of cash. The Company is subject to all of the risks inherent in a clinical-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company contracts with vendors and consultants to provide services related to the Company’s research and development. Costs and expenses incurred that represented 10% or more of research and development costs for the three months ended March 31, 2025 and 2024 consisted of the following: during the three months ended March 31, 2025, costs from three two The Company’s operating results may be materially affected by the foregoing factors."]
["Cash and Cash Equivalents, Policy [Policy Text Block]","Cash and cash equivalents As of March 31, 2025, and December 31, 2024, the Company’s cash was maintained in demand deposit forms at three financial institutions. The Company considers any highly liquid investments, such as money market funds, with an original maturity of three months or less to be cash and cash equivalents. The components of cash and cash equivalents were as follows:\nAs of March 31, 2025\nAs of December 31, 2024\nCash on deposit $ 1,427,974 $ 1,272,704\nMoney market funds (cash equivalents) 3,861,430 12,203,627\nCash and cash equivalents $ 5,289,404 $ 13,476,331 "]
["Fair Value Measurement, Policy [Policy Text Block]","Fair value measurements Accounting Standards Codification (\"ASC\") 820, Fair Value Measurements , The three levels of the fair value hierarchy under ASC 820 are described below:\n•\nLevel 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.\n•\nLevel 2 - Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.\n•\nLevel 3 - Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. In determining the fair value of equity classified warrants, the Company utilizes the Black-Scholes-Merton model using assumptions regarding volatility of the Company's common share price, expected term of the warrants, expected divided rate, and risk-free interest rates. In determining the fair value of liability classified warrants, the Company utilizes a Lattice model using assumptions regarding volatility of the Company's common share price, expected term of the warrants, expected dividend, and risk-free interest rates. These assumptions are described as:\n•\nExpected term:\n•\nExpected volatility:\n•\nExpected dividend:\n•\nRisk-free interest rate: Due to their short maturities, the carrying amounts for cash and cash equivalents, prepaid clinical trial costs, prepaid expenses and other current assets, accounts payable, accrued clinical expenses, accrued compensation, short-term debt, and other accrued liabilities approximate their fair value."]
["Clinical Trial Costs [Policy Text Block]","\n&lt;p style=\"font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;\">&lt;span style=\"text-decoration: underline; \">Clinical trial costs&lt;/span>&lt;/p>\n\n&lt;p style=\"font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;\"> &lt;/p>\n\n&lt;p style=\"font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;\">We record clinical trial costs as they are incurred. For any unbilled costs as of each reporting date, we determine the amounts to accrue by obtaining reports from the Company’s contract research organization (“CRO”) and communicating with our personnel and suppliers to identify services that have been performed, but not yet billed. We further validate the completeness of our accruals by reconciling payments and invoices, and reviewing vendor contracts and purchase orders. As necessary, we obtain milestones and percentage completion reports from vendors and will estimate the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified of the actual cost.&lt;/p>\n\n&lt;p style=\"font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;\"> &lt;/p>\n\n&lt;p style=\"font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;\">Our estimated accrued expenses are based on facts and circumstances known to us at that time. We will confirm the accuracy of our estimates with the service providers and adjust if necessary. The significant estimates in our accrued clinical trial costs include the calculation of patient visits incurred, but not yet reported by the vendor. The calculation involves the use of key inputs and assumptions such as estimated budget, estimated unreported costs based on historical trending of reported costs to date, and projected costs remaining until the conclusion of the trials.&lt;/p>\n\n&lt;p style=\"font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;\"> &lt;/p>\n\n&lt;p style=\"font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;\">These estimates are primarily based on communications with the third-party service providers, the Company’s estimates of accrued clinical trial costs and information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. The estimates are trued up to reflect the best information available at the time of the consolidated financial statement issuance. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company’s estimate of the status and timing of services performed relative to the actual status and timing of services performed may vary.&lt;/p>\n"]
["Debt, Policy [Policy Text Block]","Short-term debt In December 2024, the Company obtained new financing for certain policy premiums related to Director and Officers liability insurance. The governing agreement assigns the lender a first priority lien on and security interest in the financed policies and any additional premium required in the financed policies. The total premiums, taxes, and fees financed was $458,154. The financing arrangement has an annual percentage interest rate of 7.90% and a term of 10 months, with ten payments, inclusive of interest, payable on a monthly basis beginning January 2025 and continuing through October 2025. "]
["New Accounting Pronouncements, Policy [Policy Text Block]","New accounting pronouncements not yet adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes Improvements to Income Tax Disclosures In November 2024, the FASB issued ASU 2024-03, Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses"]

{"sheet":"Note 2 - Summary of Significa_2","index":16,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes Tables"," "]
["Schedule of Cash and Cash Equivalents [Table Text Block]","As of March 31, 2025\nAs of December 31, 2024\nCash on deposit $ 1,427,974 $ 1,272,704\nMoney market funds (cash equivalents) 3,861,430 12,203,627\nCash and cash equivalents $ 5,289,404 $ 13,476,331 "]

{"sheet":"Note 3 - Loss Per Share (Tables","index":17,"n_rows":5,"n_cols":2,"rows_kept":5,"merged":[[0,0,1,0]]}
["Note 3 - Loss Per Share (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes Tables"," "]
["Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]","Three Months Ended March 31,\n2025\n2024\nNumerator:\nNet loss $ (6,432,840 ) $ (7,433,608 )\nDenominator:\nWeighted-average common shares outstanding – basic and diluted 48,644,339 29,887,325\nNet loss per share – basic and diluted $ (0.13 ) $ (0.25 )"]
["Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]","Three Months Ended March 31,\n2025\n2024\nShares issuable upon exercise of stock options 3,454,190 1,560,574\nShares issuable upon exercise of warrants to purchase common stock (excluding 1,968,765 warrants that are exercisable for $0.0001 per warrant as of March 31, 2025 and 2024) 45,621,853 20,883,869\n49,076,043 22,444,443 "]

{"sheet":"Note 4 - Warrants (Tables)","index":18,"n_rows":4,"n_cols":2,"rows_kept":4,"merged":[[0,0,1,0]]}
["Note 4 - Warrants (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes Tables"," "]
["Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]","Warrant Issuance\nIssuance\nExercise Price\nOutstanding, December 31, 2024\nWarrant Shares Granted\nWarrant Shares Exercised\nWarrant Shares Cancelled/ Expired\nOutstanding, March 31 2025\nExpiration\nSPAC Public Warrants\nDecember 2020 $ 11.50 6,881,313 — — — 6,881,313\nDecember 2025\nJune 2021 Common Stock Warrants\nJune 2021 $ 4.125 4,445,066 — — — 4,445,066\nMay 2026\nJune 2021 Common Stock Warrants (August 2024 Amended)*\nJune 2021 $ 0.7964 2,199,975 — — — 2,199,975\nAugust 2029\nPre-Public Private Company Warrants\nDecember 2020 $ 22.99 120,456 — — — 120,456\nJuly 2025\nSeptember 2022 Private Pre-Funded Warrants\nSeptember 2022 $ 0.0001 1,383,399 — — — 1,383,399\nSeptember 2027\nSeptember 2022 Common Stock Warrants\nSeptember 2022 $ 2.40 1,383,399 — — — 1,383,399\nSeptember 2027\nNovember 2023 Common Stock Warrants\nNovember 2023 $ 5.00 1,951,220 — — — 1,951,220\nNovember, 2028\nNovember 2023 Common Stock Warrants (May 2024 Amended)**\nNovember 2023 $ 1.455 1,365,854 — — — 1,365,854\nMay 2029\nNovember 2023 Common Stock Warrants (August 2024 Amended)***\nNovember 2023 $ 0.7964 2,536,586 — — — 2,536,586\nAugust 2029\nNovember 2023 Pre-Funded Warrants\nNovember 2023 $ 0.0001 585,366 — — — 585,366\nNovember, 2028\nMay 2024 Common Stock Warrants\nMay 2024 $ 1.455 1,898,734 — — — 1,898,734\nMay 2029\nAugust 2024 Common Stock Warrants\nAugust 2024 $ 0.7964 4,761,905 — — — 4,761,905\nAugust 2029\nAugust 2024 Underwriter Warrants\nAugust 2024 $ 1.3125 238,095 — — — 238,095\nAugust 2029\nDecember 2024 Series A Common Stock Warrants\nDecember 2024 $ 1.50 6,000,000 — (55,250 ) — 5,944,750\nJune 2025\nDecember 2024 Series B Common Stock Warrants\nDecember 2024 $ 1.50 12,000,000 — (105,500 ) — 11,894,500\nDecember 2029\n47,751,368 — (160,750 ) — 47,590,618 "]

{"sheet":"Note 5 - Stockholders' Equity_2","index":19,"n_rows":7,"n_cols":2,"rows_kept":7,"merged":[[0,0,1,0]]}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes Tables"," "]
["Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]","Shares underlying outstanding warrants 47,590,618\nShares reserved for future grants under the 2020 Equity Incentive Plan 6,823,675\nShares underlying outstanding stock options 3,454,190\nTotal common stock reserved for future issuance 57,868,483 "]
["Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]","Black-Scholes-Merton Inputs\nMarch 31, 2025\nRisk-free interest rate 4.40 %\nExpected term (in years) 5.38\nExpected volatility 110.00 %\nExpected dividend yield — %"]
["Share-Based Payment Arrangement, Option, Activity [Table Text Block]","Shares Available for Grant\nNumber of Options Outstanding\nWeighted Average Exercise price per share\nWeighted Average Remaining Contractual Term in Years\nAggregate Intrinsic Value\nBalance, December 31, 2024 3,060,506 2,559,440 $ 4.07 8.88 $ 683,016\nGranted (894,750 ) 894,750 1.80\nEvergreen plan increase 4,657,919\nBalance, March 31, 2025 6,823,675 3,454,190 $ 3.48 8.95 $ 1,219\nOptions vested and exercisable at March 31, 2025 2,143,223 $ 3.98 8.72 $ 1,219 "]
["Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]","Three Months Ended, March 31\n2025\n2024\nResearch and development $ 313,862 $ 194,896\nGeneral and administrative 605,257 174,179\nTotal stock-based compensation expense $ 919,119 $ 369,075 "]

{"sheet":"Note 7 - Fair Value Measureme_2","index":20,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Note 7 - Fair Value Measurements (Tables)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Notes Tables"," "]
["Fair Value, Assets Measured on Recurring Basis [Table Text Block]","March 31, 2025\nLevel 1\nLevel 2\nLevel 3\nTotal\nAssets:\nMoney market funds (cash equivalents) $ 3,861,430 $ — $ — $ 3,861,430\nTotal assets measured and recorded at fair value $ 3,861,430 $ — $ — $ 3,861,430\nLiabilities:\nWarrant liabilities $ — $ — $ 27,816 $ 27,816\nTotal liabilities measured and recorded at fair value $ — $ — $ 27,816 $ 27,816\nDecember 31, 2024\nLevel 1\nLevel 2\nLevel 3\nTotal\nAssets:\nMoney market funds (cash equivalents) $ 12,203,627 $ — $ — $ 12,203,627\nTotal assets measured and recorded at fair value $ 12,203,627 $ — $ — $ 12,203,627\nLiabilities:\nWarrant liabilities $ — $ — $ 89,010 $ 89,010\nTotal liabilities measured and recorded at fair value $ — $ — $ 89,010 $ 89,010 "]
["Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]","Three Months Ended March 30,\n2025\n2024\nBalance, beginning of period $ 89,010 $ 806,655\nChange in fair value of warrant liabilities (61,194 ) (456,177 )\nBalance, end of period $ 27,816 $ 350,478 "]
["Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]","March 31, 2025\nDecember 31, 2024\nRisk-free interest rate 4.15 % 4.17 %\nRemaining expected term of Private Warrants 0.71 0.95\nExpected volatility (1) 163.50 % 128.70 %\nStock price on valuation date $ 0.95 $ 1.81\nExercise price $ 11.50 $ 11.50\nExpected dividend — % — %"]

{"sheet":"Note 2 - Summary of Significa_3","index":21,"n_rows":18,"n_cols":4,"rows_kept":18,"merged":[[0,0,1,0],[0,1,0,2]]}
["Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)","3 Months Ended"]
[null,"Mar. 31, 2025 USD ($)","Mar. 31, 2024 USD ($)","Dec. 31, 2024 USD ($)"]
["Working Capital",{"v":5300000,"d":"$ 5,300,000"}," "," "]
["Retained Earnings (Accumulated Deficit)",{"v":-170705890,"d":"(170,705,890)"}," ",{"v":-164273050,"d":"$ (164,273,050)"}]
["Cash",{"v":5300000,"d":"5,300,000 "}," "," "]
["Net Income (Loss) Attributable to Parent",{"v":-6432840,"d":"(6,432,840)"},{"v":-7433608,"d":"$ (7,433,608)"}," "]
["Cash, Uninsured Amount",{"v":1093816,"d":"1,093,816 "}," ",{"v":937004,"d":"$ 937,004"}]
["Financing for Liability Insurance Policy Premiums [Member]"," "," "," "]
["Debt Instrument, Face Amount",{"v":458154,"d":"$ 458,154"}," "," "]
["Debt Instrument, Interest Rate, Stated Percentage",{"v":0.079,"d":"7.90%"}," "," "]
["Research and Development Costs [Member] | Supplier Concentration Risk [Member]"," "," "," "]
["Number of Vendors",{"v":3,"d":"3 "},{"v":2,"d":"2 "}," "]
["Research and Development Costs [Member] | Supplier Concentration Risk [Member] | Vendor One [Member]"," "," "," "]
["Concentration Risk, Percentage",{"v":0.53,"d":"53%"}," "," "]
["Research and Development Costs [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member]"," "," "," "]
["Concentration Risk, Percentage",{"v":0.18,"d":"18%"},{"v":0.3,"d":"30%"}," "]
["Research and Development Costs [Member] | Supplier Concentration Risk [Member] | Vendor Three [Member]"," "," "," "]
["Concentration Risk, Percentage",{"v":0.12,"d":"12%"}," "," "]

{"sheet":"Note 2 - Summary of Significa_4","index":22,"n_rows":4,"n_cols":3,"rows_kept":4}
["Note 2 - Summary of Significant Accounting Policies and Basis of Presentation - Components of Cash and Cash Equivalents (Details) - USD ($)","Mar. 31, 2025","Dec. 31, 2024"]
["Cash on deposit",{"v":1427974,"d":"$ 1,427,974"},{"v":1272704,"d":"$ 1,272,704"}]
["Money market funds (cash equivalents)",{"v":3861430,"d":"3,861,430 "},{"v":12203627,"d":"12,203,627 "}]
["Cash and cash equivalents",{"v":5289404,"d":"$ 5,289,404"},{"v":13476331,"d":"$ 13,476,331"}]

{"sheet":"Note 3 - Loss Per Share (Detail","index":23,"n_rows":3,"n_cols":3,"rows_kept":3}
["Note 3 - Loss Per Share (Details Textual) - $ / shares","Mar. 31, 2025","Mar. 31, 2024"]
["Warrant [Member]"," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"},{"v":0.0001,"d":"$ 0.0001"}]

{"sheet":"Note 3 - Loss Per Share - Sched","index":24,"n_rows":5,"n_cols":3,"rows_kept":5,"merged":[[0,0,1,0],[0,1,0,2]]}
["Note 3 - Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Net loss",{"v":-6432840,"d":"$ (6,432,840)"},{"v":-7433608,"d":"$ (7,433,608)"}]
["Basic and diluted (in shares)",{"v":48644339,"d":"48,644,339 "},{"v":29887325,"d":"29,887,325 "}]
["Basic and diluted (in dollars per share)",{"v":-0.13,"d":"$ (0.13)"},{"v":-0.25,"d":"$ (0.25)"}]

{"sheet":"Note 3 - Loss Per Share - Antid","index":25,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Note 3 - Loss Per Share - Antidilutive Securities (Details) - shares","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Antidilutive securities (in shares)",{"v":49076043,"d":"49,076,043 "},{"v":22444443,"d":"22,444,443 "}]
["Share-Based Payment Arrangement, Option [Member]"," "," "]
["Antidilutive securities (in shares)",{"v":3454190,"d":"3,454,190 "},{"v":1560574,"d":"1,560,574 "}]
["Warrant [Member]"," "," "]
["Antidilutive securities (in shares)",{"v":45621853,"d":"45,621,853 "},{"v":20883869,"d":"20,883,869 "}]

{"sheet":"Note 3 - Loss Per Share - Ant_2","index":26,"n_rows":5,"n_cols":4,"rows_kept":5}
["Note 3 - Loss Per Share - Antidilutive Securities (Details) (Parentheticals) - $ / shares","Mar. 31, 2025","Dec. 31, 2024","Mar. 31, 2024"]
["Class of Warrant or Right, Outstanding (in shares)",{"v":47590618,"d":"47,590,618 "},{"v":47751368,"d":"47,751,368 "}," "]
["Warrant [Member]"," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",{"v":1968765,"d":"1,968,765 "}," ",{"v":1968765,"d":"1,968,765 "}]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}]

{"sheet":"Note 4 - Warrants (Details Text","index":27,"n_rows":17,"n_cols":5,"rows_kept":17,"merged":[[0,1,0,2],[15,0,15,4],[16,0,16,4]]}
["Note 4 - Warrants (Details Textual) - $ / shares","Mar. 31, 2025",null,"Aug. 31, 2024","May 31, 2024"]
["Class of Warrant or Right, Number of Securities Called by Warrants or Rights",{"v":47590618,"d":"47,590,618 "},null," "," "]
["Amended June 2021 Common Stock Warrants [Member]"," ",null," "," "]
["Class of Warrant or Right, Number of Securities Called by Warrants or Rights"," ",null,{"v":2199975,"d":"2,199,975 "}," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",{"v":0.7964,"d":"$ 0.7964"},"[1]",{"v":0.7964,"d":"$ 0.7964"}," "]
["June 2021 Common Stock Warrants [Member]"," ",null," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"," ",null,4.125," "]
["May Amended November 2023 Common Stock Warrants [Member]"," ",null," "," "]
["Class of Warrant or Right, Number of Securities Called by Warrants or Rights"," ",null," ",{"v":1365854,"d":"1,365,854 "}]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",1.455,"[2]"," ",{"v":1.455,"d":"$ 1.455"}]
["November 2023 Common Stock Warrants [Member]"," ",null," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"," ",null,{"v":5,"d":"$ 5"},{"v":5,"d":"$ 5"}]
["August Amended November 2023 Common Stock Warrants [Member]"," ",null," "," "]
["Class of Warrant or Right, Number of Securities Called by Warrants or Rights"," ",null,{"v":2536586,"d":"2,536,586 "}," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",{"v":0.7964,"d":"$ 0.7964"},"[3]",{"v":0.7964,"d":"$ 0.7964"}," "]
[]
["[1]* In August 2024, 2,199,975 of these warrants were modified to reduce the exercise price from $4.125 per warrant share, to $0.7964 per warrant share and to extend the expiration of these warrants from May 2026 to August 2029.[2]** In May 2024, 1,365,854 of these warrants were modified to reduce the exercise price from $5.00 per warrant share, to $1.455 per warrant share and to extend the expiration of these warrants from November 2028 to May 2029.[3]*** In August 2024, 2,536,586 of these warrants (separate from the May 2024 modification) were modified to reduce the exercise price from $5.00 per warrant share, to $0.7964 per warrant share and to extend the expiration of these warrants from November 2028 to August 2029."]

{"sheet":"Note 4 - Warrants - Warrants Ou","index":28,"n_rows":162,"n_cols":7,"rows_kept":162,"merged":[[0,0,1,1],[0,2,0,3],[1,2,1,3],[160,0,160,5],[161,0,161,5]]}
["Note 4 - Warrants - Warrants Outstanding (Details) - $ / shares",null,"3 Months Ended"]
[null,null,"Mar. 31, 2025",null,"Dec. 31, 2024","Aug. 31, 2024","May 31, 2024"]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":47590618,"d":"47,590,618 "},null,{"v":47751368,"d":"47,751,368 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":160750,"d":"160,750 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":47590618,"d":"47,590,618 "},null,{"v":47751368,"d":"47,751,368 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":-160750,"d":"(160,750)"},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":11.5,"d":"$ 11.5"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":6881313,"d":"6,881,313 "},null,{"v":6881313,"d":"6,881,313 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":6881313,"d":"6,881,313 "},null,{"v":6881313,"d":"6,881,313 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["June 2021 Common Stock Warrants, Post Amendment [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":4.125,"d":"$ 4.125"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":4445066,"d":"4,445,066 "},null,{"v":4445066,"d":"4,445,066 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":4445066,"d":"4,445,066 "},null,{"v":4445066,"d":"4,445,066 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Amended June 2021 Common Stock Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":0.7964,"d":"$ 0.7964"},"[1]"," ",{"v":0.7964,"d":"$ 0.7964"}," "]
["Class of Warrant or Right, Outstanding (in shares)","[1]",{"v":2199975,"d":"2,199,975 "},null,{"v":2199975,"d":"2,199,975 "}," "," "]
["SPAC Public Warrants (in shares)","[1]",{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)","[1]",{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)","[1]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding","[1]",{"v":2199975,"d":"2,199,975 "},null,{"v":2199975,"d":"2,199,975 "}," "," "]
["Class of Warrant or Right, Issued During Period","[1]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period","[1]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period","[1]",{"v":0,"d":"0 "},null," "," "," "]
["Pre Public Private Company Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":22.99,"d":"$ 22.99"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":120456,"d":"120,456 "},null,{"v":120456,"d":"120,456 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":120456,"d":"120,456 "},null,{"v":120456,"d":"120,456 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["September 2022 Private Pre Funded Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":0.0001,"d":"$ 0.0001"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":1383399,"d":"1,383,399 "},null,{"v":1383399,"d":"1,383,399 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":1383399,"d":"1,383,399 "},null,{"v":1383399,"d":"1,383,399 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["September 2022 Common Stock Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":2.4,"d":"$ 2.4"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":1383399,"d":"1,383,399 "},null,{"v":1383399,"d":"1,383,399 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":1383399,"d":"1,383,399 "},null,{"v":1383399,"d":"1,383,399 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["November 2023 Common Stock Warrants, Post Amendment [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":5,"d":"$ 5"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":1951220,"d":"1,951,220 "},null,{"v":1951220,"d":"1,951,220 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":1951220,"d":"1,951,220 "},null,{"v":1951220,"d":"1,951,220 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["May Amended November 2023 Common Stock Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":1.455,"d":"$ 1.455"},"[2]"," "," ",{"v":1.455,"d":"$ 1.455"}]
["Class of Warrant or Right, Outstanding (in shares)","[2]",{"v":1365854,"d":"1,365,854 "},null,{"v":1365854,"d":"1,365,854 "}," "," "]
["SPAC Public Warrants (in shares)","[2]",{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)","[2]",{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)","[2]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding","[2]",{"v":1365854,"d":"1,365,854 "},null,{"v":1365854,"d":"1,365,854 "}," "," "]
["Class of Warrant or Right, Issued During Period","[2]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period","[2]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period","[2]",{"v":0,"d":"0 "},null," "," "," "]
["August Amended November 2023 Common Stock Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":0.7964,"d":"$ 0.7964"},"[3]"," ",{"v":0.7964,"d":"$ 0.7964"}," "]
["Class of Warrant or Right, Outstanding (in shares)","[3]",{"v":2536586,"d":"2,536,586 "},null,{"v":2536586,"d":"2,536,586 "}," "," "]
["SPAC Public Warrants (in shares)","[3]",{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)","[3]",{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)","[3]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding","[3]",{"v":2536586,"d":"2,536,586 "},null,{"v":2536586,"d":"2,536,586 "}," "," "]
["Class of Warrant or Right, Issued During Period","[3]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period","[3]",{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period","[3]",{"v":0,"d":"0 "},null," "," "," "]
["November 2023 Pre Funded Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":0.0001,"d":"$ 0.0001"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":585366,"d":"585,366 "},null,{"v":585366,"d":"585,366 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":585366,"d":"585,366 "},null,{"v":585366,"d":"585,366 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["May 2024 Common Stock Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":1.455,"d":"$ 1.455"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":1898734,"d":"1,898,734 "},null,{"v":1898734,"d":"1,898,734 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":1898734,"d":"1,898,734 "},null,{"v":1898734,"d":"1,898,734 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["August 2024 Common Stock Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":0.7964,"d":"$ 0.7964"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":4761905,"d":"4,761,905 "},null,{"v":4761905,"d":"4,761,905 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":4761905,"d":"4,761,905 "},null,{"v":4761905,"d":"4,761,905 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["The August 2024 Underwriter Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":1.3125,"d":"$ 1.3125"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":238095,"d":"238,095 "},null,{"v":238095,"d":"238,095 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":238095,"d":"238,095 "},null,{"v":238095,"d":"238,095 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["The December 2024 Series A Common Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":1.5,"d":"$ 1.5"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":5944750,"d":"5,944,750 "},null,{"v":6000000,"d":"6,000,000 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":-55250,"d":"(55,250)"},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":5944750,"d":"5,944,750 "},null,{"v":6000000,"d":"6,000,000 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":55250,"d":"55,250 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["The December 2024 Series B Common Warrants [Member]",null," ",null," "," "," "]
["Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",null,{"v":1.5,"d":"$ 1.5"},null," "," "," "]
["Class of Warrant or Right, Outstanding (in shares)",null,{"v":11894500,"d":"11,894,500 "},null,{"v":12000000,"d":"12,000,000 "}," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":-105500,"d":"(105,500)"},null," "," "," "]
["SPAC Public Warrants (in shares)",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Outstanding",null,{"v":11894500,"d":"11,894,500 "},null,{"v":12000000,"d":"12,000,000 "}," "," "]
["Class of Warrant or Right, Issued During Period",null,{"v":0,"d":"0 "},null," "," "," "]
["Class of Warrant or Right, Exercised During Period",null,{"v":105500,"d":"105,500 "},null," "," "," "]
["Class of Warrant or Right, Expired During Period",null,{"v":0,"d":"0 "},null," "," "," "]
[]
["[1]* In August 2024, 2,199,975 of these warrants were modified to reduce the exercise price from $4.125 per warrant share, to $0.7964 per warrant share and to extend the expiration of these warrants from May 2026 to August 2029.[2]** In May 2024, 1,365,854 of these warrants were modified to reduce the exercise price from $5.00 per warrant share, to $1.455 per warrant share and to extend the expiration of these warrants from November 2028 to May 2029.[3]*** In August 2024, 2,536,586 of these warrants (separate from the May 2024 modification) were modified to reduce the exercise price from $5.00 per warrant share, to $0.7964 per warrant share and to extend the expiration of these warrants from November 2028 to August 2029."]

{"sheet":"Note 5 - Stockholders' Equity_3","index":29,"n_rows":16,"n_cols":5,"rows_kept":16,"merged":[[0,0,1,0],[0,2,0,3]]}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation (Details Textual) - USD ($)",null,"3 Months Ended"]
[null,"Jan. 01, 2025","Mar. 31, 2025","Mar. 31, 2024","Dec. 31, 2024"]
["Common Stock, Shares Authorized"," ",{"v":315000000,"d":"315,000,000 "}," ",{"v":315000000,"d":"315,000,000 "}]
["Common Stock, Par or Stated Value Per Share"," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}]
["Preferred Stock, Shares Authorized"," ",{"v":10000000,"d":"10,000,000 "}," ",{"v":10000000,"d":"10,000,000 "}]
["Preferred Stock, Par or Stated Value Per Share"," ",{"v":0.0001,"d":"$ 0.0001"}," ",{"v":0.0001,"d":"$ 0.0001"}]
["Common Stock, Shares, Outstanding"," ",{"v":46739949,"d":"46,739,949 "}," ",{"v":46579199,"d":"46,579,199 "}]
["Preferred Stock, Shares Outstanding"," ",{"v":0,"d":"0 "}," ",{"v":0,"d":"0 "}]
["Share-Based Payment Arrangement, Expense"," ",{"v":919119,"d":"$ 919,119"},{"v":369075,"d":"$ 369,075"}," "]
["Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"," ",{"v":2700000,"d":"$ 2,700,000"}," "," "]
["Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"," ","1 year 10 months 24 days"," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Fair Value"," ",{"v":1480000,"d":"$ 1,480,000"},{"v":0,"d":"$ 0"}," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period"," ","10 years"," "," "]
["Equity Incentive Plan 2020 [Member]"," "," "," "," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",{"v":4657919,"d":"4,657,919 "}," "," "," "]
["Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percent of Increase",{"v":10,"d":"1,000%"}," "," "," "]

{"sheet":"Note 5 - Stockholders' Equity_4","index":30,"n_rows":6,"n_cols":2,"rows_kept":6}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation - Summary of Common Stock Reserved for Future Issuance (Details)","Mar. 31, 2025 shares"]
["Shares underlying outstanding warrants (in shares)",{"v":47590618,"d":"47,590,618 "}]
["Total common stock reserved for future issuance (in shares)",{"v":57868483,"d":"57,868,483 "}]
["Stock options outstanding (in shares)",{"v":3454190,"d":"3,454,190 "}]
["Equity Incentive Plan 2020 [Member]"," "]
["Total common stock reserved for future issuance (in shares)",{"v":6823675,"d":"6,823,675 "}]

{"sheet":"Note 5 - Stockholders' Equity_5","index":31,"n_rows":6,"n_cols":2,"rows_kept":6,"merged":[[0,0,1,0]]}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation - Valuation Assumptions (Details)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Risk-free interest rate",{"v":0.044,"d":"4.40%"}]
["Expected term (in years) (Year)","5 years 4 months 17 days"]
["Expected volatility",{"v":1.1,"d":"110%"}]
["Expected dividend yield",{"v":0,"d":"0%"}]

{"sheet":"Note 5 - Stockholders' Equity_6","index":32,"n_rows":20,"n_cols":3,"rows_kept":20,"merged":[[0,0,1,0]]}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation - Stock Option Activity (Details) - USD ($)","3 Months Ended","12 Months Ended"]
[null,"Mar. 31, 2025","Dec. 31, 2024"]
["Balance, March 31, 2025 (in shares)",{"v":3454190,"d":"3,454,190 "}," "]
["Share-Based Payment Arrangement, Option [Member]"," "," "]
["Balance, shares available for grant (in shares)",{"v":3060506,"d":"3,060,506 "}," "]
["Balance, number of options outstanding (in shares)",{"v":2559440,"d":"2,559,440 "}," "]
["Balance, weighted average exercise price (in dollars per share)",{"v":4.07,"d":"$ 4.07"}," "]
["Balance, weighted average remaining contractual term (Year)","8 years 11 months 12 days","8 years 10 months 17 days"]
["Balance, aggregate intrinsic value",{"v":1219,"d":"$ 1,219"},{"v":683016,"d":"$ 683,016"}]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)",{"v":-894750,"d":"(894,750)"}," "]
["Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)",{"v":894750,"d":"894,750 "}," "]
["Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)",{"v":1.8,"d":"$ 1.8"}," "]
["Authorized, shares available for grant (in shares)",{"v":4657919,"d":"4,657,919 "}," "]
["Balance, March 31, 2025 (in shares)",{"v":6823675,"d":"6,823,675 "},{"v":3060506,"d":"3,060,506 "}]
["Balance, March 31, 2025 (in shares)",{"v":3454190,"d":"3,454,190 "},{"v":2559440,"d":"2,559,440 "}]
["Balance, March 31, 2025 (in dollars per share)",{"v":3.48,"d":"$ 3.48"},{"v":4.07,"d":"$ 4.07"}]
["Options exercisable, weighted average exercise price per share (in shares)",{"v":2143223,"d":"2,143,223 "}," "]
["Options exercisable, weighted average remaining contractual term (in dollars per share)",{"v":3.98,"d":"$ 3.98"}," "]
["Options exercisable, aggregate intrinsic value (Year)","8 years 8 months 19 days"," "]
["Options exercisable, number of options",{"v":1219,"d":"$ 1,219"}," "]

{"sheet":"Note 5 - Stockholders' Equity_7","index":33,"n_rows":7,"n_cols":3,"rows_kept":7,"merged":[[0,0,1,0],[0,1,0,2]]}
["Note 5 - Stockholders' Equity, Stock Option Plans, And Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Stock-based compensation expense",{"v":919119,"d":"$ 919,119"},{"v":369075,"d":"$ 369,075"}]
["Research and Development Expense [Member]"," "," "]
["Stock-based compensation expense",{"v":313862,"d":"313,862 "},{"v":194896,"d":"194,896 "}]
["General and Administrative Expense [Member]"," "," "]
["Stock-based compensation expense",{"v":605257,"d":"$ 605,257"},{"v":174179,"d":"$ 174,179"}]

{"sheet":"Note 6 - Commitments and Cont_2","index":34,"n_rows":9,"n_cols":4,"rows_kept":9,"merged":[[0,0,1,0],[0,2,0,3]]}
["Note 6 - Commitments and Contingencies (Details Textual) - USD ($)",null,"3 Months Ended"]
[null,"Jan. 01, 2025","Mar. 31, 2025","Mar. 31, 2024"]
["Operating Lease, Expense"," ",{"v":13800,"d":"$ 13,800"},{"v":11200,"d":"$ 11,200"}]
["Corporate Office Lease 2 [Member]"," "," "," "]
["Lessee, Operating Lease, Term of Contract"," ","12 months"," "]
["Lessee, Operating Lease, Monthly Lease Payment"," ",{"v":4300,"d":"$ 4,300"}," "]
["Corporate Office Lease [Member]"," "," "," "]
["Lessee, Operating Lease, Monthly Lease Payment",{"v":4600,"d":"$ 4,600"}," "," "]
["Lessee, Operating Lease, Renewal Term","12 months"," "," "]

{"sheet":"Note 7 - Fair Value Measureme_3","index":35,"n_rows":5,"n_cols":3,"rows_kept":5}
["Note 7 - Fair Value Measurements (Details Textual) - USD ($)","Mar. 31, 2025","Dec. 31, 2024"]
["Class of Warrant or Right, Number of Securities Called by Warrants or Rights",{"v":47590618,"d":"47,590,618 "}," "]
["Private Warrants [Member]"," "," "]
["Class of Warrant or Right, Number of Securities Called by Warrants or Rights",{"v":556313,"d":"556,313 "}," "]
["Warrants and Rights Outstanding, Fair Value",{"v":27816,"d":"$ 27,816"},{"v":89010,"d":"$ 89,010"}]

{"sheet":"Note 7 - Fair Value Measureme_4","index":36,"n_rows":20,"n_cols":3,"rows_kept":20}
["Note 7 - Fair Value Measurements - Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)","Mar. 31, 2025","Dec. 31, 2024"]
["Total assets measured and recorded at fair value",{"v":3861430,"d":"$ 3,861,430"},{"v":12203627,"d":"$ 12,203,627"}]
["Warrant liabilities",{"v":27816,"d":"27,816 "},{"v":89010,"d":"89,010 "}]
["Total liabilities measured and recorded at fair value",{"v":27816,"d":"27,816 "},{"v":89010,"d":"89,010 "}]
["Fair Value, Inputs, Level 1 [Member]"," "," "]
["Total assets measured and recorded at fair value",{"v":3861430,"d":"3,861,430 "},{"v":12203627,"d":"12,203,627 "}]
["Fair Value, Inputs, Level 2 [Member]"," "," "]
["Total assets measured and recorded at fair value",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Fair Value, Inputs, Level 3 [Member]"," "," "]
["Total assets measured and recorded at fair value",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Warrant liabilities",{"v":27816,"d":"27,816 "},{"v":89010,"d":"89,010 "}]
["Total liabilities measured and recorded at fair value",{"v":27816,"d":"27,816 "},{"v":89010,"d":"89,010 "}]
["Money Market Funds [Member]"," "," "]
["Money market funds (cash equivalents)",{"v":3861430,"d":"3,861,430 "},{"v":12203627,"d":"12,203,627 "}]
["Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]"," "," "]
["Money market funds (cash equivalents)",{"v":3861430,"d":"3,861,430 "},{"v":12203627,"d":"12,203,627 "}]
["Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]"," "," "]
["Money market funds (cash equivalents)",{"v":0,"d":"0 "},{"v":0,"d":"0 "}]
["Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]"," "," "]
["Money market funds (cash equivalents)",{"v":0,"d":"$ 0"},{"v":0,"d":"$ 0"}]

{"sheet":"Note 7 - Fair Value Measureme_5","index":37,"n_rows":5,"n_cols":3,"rows_kept":5,"merged":[[0,0,1,0],[0,1,0,2]]}
["Note 7 - Fair Value Measurements - Fair Value on Recurring Basis Unobservable Input Reconciliation (Details) - Fair Value, Recurring [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($)","3 Months Ended"]
[null,"Mar. 31, 2025","Mar. 31, 2024"]
["Balance, beginning of period",{"v":89010,"d":"$ 89,010"},{"v":806655,"d":"$ 806,655"}]
["Change in fair value of warrant liabilities",{"v":-61194,"d":"(61,194)"},{"v":-456177,"d":"(456,177)"}]
["Balance, end of period",{"v":27816,"d":"$ 27,816"},{"v":350478,"d":"$ 350,478"}]

{"sheet":"Note 7 - Fair Value Measureme_6","index":38,"n_rows":11,"n_cols":3,"rows_kept":11}
["Note 7 - Fair Value Measurements - Key Inputs (Details) - Private Warrants [Member]","Mar. 31, 2025","Dec. 31, 2024"]
["Measurement Input, Risk Free Interest Rate [Member]"," "," "]
["Warrants, measurement input",0.0415,0.0417]
["Measurement Input, Expected Term [Member]"," "," "]
["Warrants, measurement input",0.71,0.95]
["Measurement Input, Price Volatility [Member]"," "," "]
["Warrants, measurement input",1.635,1.287]
["Measurement Input, Share Price [Member]"," "," "]
["Warrants, measurement input",0.95,1.81]
["Measurement Input, Exercise Price [Member]"," "," "]
["Warrants, measurement input",11.5,11.5]

{"sheet":"Note 8 -Segment Information (De","index":39,"n_rows":3,"n_cols":2,"rows_kept":3,"merged":[[0,0,1,0]]}
["Note 8 -Segment Information (Details Textual)","3 Months Ended"]
[null,"Mar. 31, 2025"]
["Number of Operating Segments",{"v":1,"d":"1 "}]